Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1988 4
1989 2
1991 3
1992 2
1993 6
1994 1
1995 2
1996 2
1997 3
1998 1
1999 2
2000 3
2001 4
2002 4
2005 1
2006 9
2007 7
2008 16
2009 11
2010 10
2011 13
2012 10
2013 15
2014 20
2015 17
2016 9
2017 18
2018 12
2019 9
2020 5
2021 6
Text availability
Article attribute
Article type
Publication date

Search Results

216 results
Results by year
Filters applied: . Clear all
Page 1
A new normalization for Nanostring nCounter gene expression data.
Molania R, Gagnon-Bartsch JA, Dobrovic A, Speed TP. Molania R, et al. Among authors: dobrovic a. Nucleic Acids Res. 2019 Jul 9;47(12):6073-6083. doi: 10.1093/nar/gkz433. Nucleic Acids Res. 2019. PMID: 31114909 Free PMC article.
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G. Alsop K, et al. Among authors: dobrovic a. J Clin Oncol. 2012 Jul 20;30(21):2654-63. doi: 10.1200/JCO.2011.39.8545. Epub 2012 Jun 18. J Clin Oncol. 2012. PMID: 22711857 Free PMC article.
A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma.
Stringer BW, Day BW, D'Souza RCJ, Jamieson PR, Ensbey KS, Bruce ZC, Lim YC, Goasdoué K, Offenhäuser C, Akgül S, Allan S, Robertson T, Lucas P, Tollesson G, Campbell S, Winter C, Do H, Dobrovic A, Inglis PL, Jeffree RL, Johns TG, Boyd AW. Stringer BW, et al. Among authors: dobrovic a. Sci Rep. 2019 Mar 20;9(1):4902. doi: 10.1038/s41598-019-41277-z. Sci Rep. 2019. PMID: 30894629 Free PMC article.
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS), deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL. Kondrashova O, et al. Among authors: dobrovic a. Nat Commun. 2018 Sep 28;9(1):3970. doi: 10.1038/s41467-018-05564-z. Nat Commun. 2018. PMID: 30266954 Free PMC article.
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
Young RJ, Waldeck K, Martin C, Foo JH, Cameron DP, Kirby L, Do H, Mitchell C, Cullinane C, Liu W, Fox SB, Dutton-Regester K, Hayward NK, Jene N, Dobrovic A, Pearson RB, Christensen JG, Randolph S, McArthur GA, Sheppard KE. Young RJ, et al. Among authors: dobrovic a. Pigment Cell Melanoma Res. 2014 Jul;27(4):590-600. doi: 10.1111/pcmr.12228. Epub 2014 Mar 6. Pigment Cell Melanoma Res. 2014. PMID: 24495407 Clinical Trial.
216 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page